<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34595940</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1542-6270</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>56</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Annals of pharmacotherapy</Title>
          <ISOAbbreviation>Ann Pharmacother</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Risk of Gastrointestinal Bleeding on Treatment With Statin Alone or With Concomitant Administration of Warfarin: A Systematic Review and Meta-analysis of 5.3 Million Participants.</ArticleTitle>
        <Pagination>
          <StartPage>820</StartPage>
          <EndPage>830</EndPage>
          <MedlinePgn>820-830</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/10600280211049727</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aimed to comprehensively evaluate the risk of gastrointestinal bleeding (GIB) with statin monotherapy or with concomitant warfarin use.</AbstractText>
          <AbstractText Label="DATA SOURCES" NlmCategory="UNASSIGNED">PubMed, Web of Science, and EMBASE (via Scopus) were searched for observational studies that reported the risk of GIB in adults on statin therapy or with concomitant warfarin use until August 28, 2021.</AbstractText>
          <AbstractText Label="STUDY SELECTION AND DATA EXTRACTION" NlmCategory="UNASSIGNED">Observational studies evaluating the risk of GIB in adults (age &gt;18 years) on statin medication or concomitant use with warfarin were included.</AbstractText>
          <AbstractText Label="DATA SYNTHESIS" NlmCategory="UNASSIGNED">In all, 14 studies with a total of 5 235 123 participants, reporting 48 677 GIB events (43 734 from statin users and 4943 from users of statin combined with warfarin), were included in the analyses. The pooled analysis revealed no difference in the risk of GIB with statin monotherapy (relative risk [RR]: 0.65; 95% CI: 0.42-1.02) or concomitant statin + warfarin use (RR: 0.97; 95% CI: 0.91-1.02). Prior use of statin was not associated with GIB risk (RR: 0.88; 95% CI: 0.63-1.22), whereas a shorter duration of statin use (&lt;5 years) was associated with a lower risk of GIB (RR: 0.42; 95% CI: 0.18-0.97).</AbstractText>
          <AbstractText Label="RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE" NlmCategory="UNASSIGNED">This analysis provides strong evidence on the association between statin use (with/without warfarin) and risk of GIB.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Statin alone or combined with warfarin was not significantly associated with either an increased or decreased risk of GIB. The GIB risk was significantly lower when statins were used for a short duration (&lt;5 years). The putative relationship between statins and GIB in warfarin users warrant further investigation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bhagavathula</LastName>
            <ForeName>Akshaya Srikanth</ForeName>
            <Initials>AS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vidyasaga</LastName>
            <ForeName>Kota</ForeName>
            <Initials>K</Initials>
            <Identifier Source="ORCID">0000-0002-7866-0936</Identifier>
            <AffiliationInfo>
              <Affiliation>Kakatiya University, Warangal, India.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gebreyohannes</LastName>
            <ForeName>Eyob Alemayehu</ForeName>
            <Initials>EA</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pharmacy, School of Allied Health, University of Western Australia, WA, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tesfaye</LastName>
            <ForeName>Wubshet</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0001-7208-2330</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Canberra, Australian Capital Territory, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Ann Pharmacother</MedlineTA>
        <NlmUniqueID>9203131</NlmUniqueID>
        <ISSNLinking>1060-0280</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006471" MajorTopicYN="N">Gastrointestinal Hemorrhage</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019161" MajorTopicYN="Y">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="Y">Warfarin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anticoagulant</Keyword>
        <Keyword MajorTopicYN="N">bleeding</Keyword>
        <Keyword MajorTopicYN="N">gastrointestinal hemorrhage</Keyword>
        <Keyword MajorTopicYN="N">hydroxymethylglutaryl-CoA reductase inhibitors</Keyword>
        <Keyword MajorTopicYN="N">review</Keyword>
        <Keyword MajorTopicYN="N">warfarin</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>8</Hour>
          <Minute>39</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34595940</ArticleId>
        <ArticleId IdType="doi">10.1177/10600280211049727</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
